Tipranavir: A new protease inhibitor for the pediatric population

Expert Review of Anti-Infective Therapy

Volumn 6, Issue 6, 2008, Pages 797-803

  Courter, Joshua D ^a,b   Girotto, Jennifer E ^a,b   Salazar, Juan C ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Farmington   (United States)

Author keywords

HAART; HIV; Pediatric; Protease inhibitor; Tipranavir

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE PLUS RITONAVIR; ANTIVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIDINE DERIVATIVE; PYRONE DERIVATIVE;

ABDOMINAL PAIN; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; BLEEDING; BODY FAT DISTRIBUTION; BODY FAT REDISTRIBUTION; BRAIN HEMORRHAGE; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LIPIDOSIS; LIVER TOXICITY; NAUSEA; NEUTROPENIA; PANCREATITIS; PARESTHESIA; PHARMACODYNAMICS; PHENOTYPE; RHINOPHARYNGITIS; SIDE EFFECT; SURVIVAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS LOAD; VIRUS REPLICATION; VOMITING; ADOLESCENT; CHILD; PRESCHOOL CHILD; REVIEW;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; PYRIDINES; PYRONES;

EID: 59449090891     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.6.6.797     Document Type: Article

References (27)

1. Epidemiology of HIV/AIDS - United States, 1981-2005. MMWR Morb. Mortal. Wkly Rep. 55(21), 589-592 (2006).
2. Brogly S, Williams P, Seage GR III, Oleske JM, Van DR, McIntosh K. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA 293(18), 2213-2220 (2005).
3. Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338(18), 1281-1292 (1998).
4. Petersen ML, Wang Y, van der Laan MJ, Rhee SY, Shafer RW, Fessel WJ. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. AIDS 21(12), 1547-1554 (2007).
5. Gallant JE. Protease-inhibitor boosting in the treatment-experienced patient. AIDS Rev. 6(4), 226-333 (2004).
6. Sension M, Piliero PJ. Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients. J. Assoc. Nurses AIDS Care 18(1), 36-47 (2007).
7. Kuritzkes DR. HIV resistance: frequency, testing, mechanisms. Top. HIV Med. 15(5), 150-154 (2007).
8. Pham PA. FDA approves Aptivus (tipranavir). Hopkins HIV Rep. 17(4), 6-7 (2005).
9. Turner SR, Strohbach JW, Tommasi RA et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 41(18), 3467-3476 (1998).
10. Poppe SM, Slade DE, Chong KT et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 41(5), 1058-1063 (1997).
11. Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimize pharmacotherapy. J. Infect. Dis. 175, 583-589 (1997).
12. Macgregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, McCallister S. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials 5(6), 371-382 (2004).
13. 2bid. Presented at: Conference on Retroviruses and Opportunistic Infections 2006. Denver, CO, USA, 5-8 February 2006 Abstract R-136).
14. De Requena DG, Bonora S, Calcagno A et al. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. Antimicrob. Agents Chemother. 52(3), 1066-1071 (2008).
15. Salazar JC, Cahn P, Della Negra M et al. Predictors of response to TPV/r in pediatric patients: results of PACTG1051/BI1182.14. Presented at: Conference on Retroviruses and Opportunistic Infections 2007. Los Angeles, CA, USA, 25-28 February 2007 (Poster 733).
16. Baldwin JR, Boron MT, Wang J, Schneck DW, Hopkins NK. Effects of food and antacid on-bioavailability of the protease inhibitor. PNU-140690 in healthy volunteers. Presented at: Conference on Retroviruses and Opportunistic Infections 1998. Chicago, IL, USA, 1-5 February 1998 (Abstract).
17. Sabo JP, Huettner S, MacGregor TR, Wruck J. Evaluation of the bioavailability of tipranavir/ritonavir (TPV/r) 500 mg/200 mg oral solution (OS): comparison to TPV capsules and the influence of food intake in healthy volunteers. Presented at: 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Quebec, Canada, 28-30 April 2005 (Poster 3.8).
18. Flexner C, Bate G, Kirkpatrick P. Tipranavir. Nat. Rev. Drug Discov. 4(12), 955-956 (2005).
19. Vourvahis M, Dumond J, Patterson K et al. Effectr of tipranavir/ ritonavir (TPV/r) on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein (P-gp): implications for drug interactions. Presented at: Conference on Retroviruses and Opportunistic Infections 2007. Los Angeles, CA, USA, 25-28 February 2007.
20. Chen L, Sabo JP, Philip E, Mao Y et al. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir. Antimicrob. Agents Chemother. 51(7), 2436-2444 (2007).
21. King JR, Acosta EP. Tipranavir a novel nonpeptidic protease inhibitor of HIV. Clin. Pharmacokinet. 45(7), 665-682 (2006).
22. Salazar JC, Cahn P, Yogev R et al. Efficacy, safety, and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS 22, 1789-1798 (2008).
23. Salazar JC, Cahn P, Della Negra M et al. Efficacy and safety results of 48 weeks of treatment with APTIVUS oral solution co-administered with low dose ritonavir (APTIVUS/r) in children and teenagers (phase I/IIa study). Presented at: XVI International AIDS conference. Toronto, Canada, 13-18 August 2006 (Abstract WEAB0301).
24. Giaquinto C, Notheis G, Negra MD, Jelaska A, Azienda JM. Efficacy of tipranavir oral solution co-administered with low dose ritonavir (TPV/r) is similar in all age groups of children and teenagers. Presented at: Eighth International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 12-16 November 2006 (Abstract 190).
25. Salazar JC, Cahn P, Giaquinto C, Yogev R, Miki J, Jelaska A. Efficacy and safety profile of APTIVUS oral solution or capsules co-administered with low dose ritonavir (APTIVUS/r) in treatment experienced children and teenagers after two years of treatment (Phase I/IIa study).Presented at: XVII International AIDS Conference. Mexico City, Mexico, 3-8 August 2008 (Abstract MOPE0187).
26. Fultz SL, Zingmond D, Gordon K et al. Evaluation of intracranial hemorrhage in 49,610 HIV-infected veterans and California medicaid recipients. Presented at: Conference on Retroviruses and Opportunistic Infections 2007. Los Angeles, CA, USA, 25-28 February 2007.
27. Graff J, von HN, Kuczka K et al. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J. Antimicrob. Chemother. 61(2), 394-399 (2008).